Adrenal Gland Neoplasms Clinical Trial
Official title:
The COMETE Network, Towards an Easy-to-use Adrenal Cancer/Tumor Identity Card
Malignant pheochromocytoma/paraganglioma (MPP) and adrenocortical carcinoma (ACC) are two
rare cancer entities with a very unfavorable prognosis. The knowledge on these rare cancers
improved thanks to the French COMETE network originally based on two clinical centers (HEGP
and Cochin) well organized for clinical and biological samples collection. Over the last 10
years, the COMETE key partners deciphered molecular mechanisms of tumorigenesis and
oncogenesis of these tumors and identified molecular signatures discriminating between benign
and malignant cancers by integrated genomic approaches. This strategy was highly successful
in delivering new diagnostic applications of genomics technologies that now appear as
potentially suitable for rapid implementation in routine clinical care.
The main objective of COMETE-TACTIC is to provide an easy-to-use "identity card" of the
adrenal tumors that will allow a personalized "à la carte" management of the patient and,
when indicated, to the indication of the most accurate molecular targeted therapy.
We hypothesize that the improvement of MPP and ACC diagnosis and of the therapeutic options
proposed to affected patients will require,
1. the transfer to routine practice and the prospective validation of the novel diagnostic
and predictive biomarkers issued from recent discoveries (genetics, genomics,
histological biomarkers);
2. the implementation of the translational research projects based on the COMETE collection
to identify circulating diagnostic, prognostic and therapeutic genetic and metabolic
biomarkers that could be used as non-invasive "liquid biopsies".
Malignant pheochromocytoma/paraganglioma (MPP) and adrenocortical carcinoma (ACC) are two
rare cancer entities with a very unfavorable prognosis. The knowledge on these rare cancers
improved thanks to the French COMETE ('COrtex, MEdulla Tumors Endocrines') network originally
based on two clinical centers (HEGP and Cochin) well organized for clinical and biological
samples collection. Over the last 10 years, the COMETE key partners deciphered molecular
mechanisms of tumorigenesis and oncogenesis of these tumors and identified molecular
signatures discriminating between benign and malignant cancers by integrated genomic
approaches. COMETE has published more than 200 papers and performed seminal work on the
pathophysiology and the genetics of MPP and ACC published in high-impact journals.
This strategy was highly successful in delivering new diagnostic applications of genomics
technologies that now appear as potentially suitable for rapid implementation in routine
clinical care.
The main objective of COMETE-TACTIC program is to design and validate an easy-to-use
"identity card" classifying MPP and ACC in clinical routine, using molecular genomic and
metabolomic tools combined with histopathological-based tests, to provide a real help for
early diagnosis, prognostic as well as a personalized "à la carte" management and treatment
to patients with malignant adrenal tumors. Seven teams, with an expertise in genomics of
adrenal tumors, or in metabolomics approaches, or in clinical research and statistical
analyses collaborate in COMETE-TACTIC. COMETE-TACTIC will be based on an already constituted
large cohort of 850 patients that will be enlarged by the prospective enrolment of new cases
and biological samples (300 to 450 new cases during the 3 years of the project) via 21 French
expert and/or competence centers of COMETE-Cancer Reference center.
Previous COMETE basic studies provided important new insight for the understanding of
molecular mechanisms responsible for MPP or ACC. With the transfer of "Omics"-based tests
from research laboratories to clinical practice, COMETE-TACTIC is the next step toward a
personalized medicine for patients with MPP and ACC. COMETE-TACTIC should speed the transfer
in routine clinical care of new biomarkers based on cutting-edge technologies combining
advanced pathology assessment and targeted genomics and metabolomics to diagnose malignancy
and predict outcome, and thereby facilitating a more accurate, rapid and reliable diagnostic
work-up for patients. This personalized management will help to avoid delayed diagnosis and
to direct clinical decisions resulting in a better health outcome for the patients.
COMETE-TACTIC will offer the access to a precise molecular classification of MPP and ACC that
should guide targeted therapies. Finally, COMETE-TACTIC will investigate for the first time
the impact of circulating biomarkers for the diagnosis and prognostic of adrenal cancers that
will be further tested as biomarkers of response to targeted therapies.
;
| Status | Clinical Trial | Phase | |
|---|---|---|---|
| Enrolling by invitation |
NCT01465425 -
Extracolonic Findings on Computed Tomography (CT) Colonography
|
||
| Terminated |
NCT01348698 -
Evaluation of Molecular Markers in Adrenal Tumors
|
||
| Completed |
NCT00037843 -
Iodine I-131 Iodocholesterol, Its Use in Adrenal Screening
|
Phase 3 | |
| Recruiting |
NCT02010957 -
Combined FDG-PET and 123I-Iodometomidate Imaging for Adrenal Neoplasia
|
Phase 3 |